Scott Wolchko | President and Chief Executive Officer |
Dan Shoemaker | Chief Scientific Officer |
Bob Valamehr | Chief Development Officer |
Wayne Chu | Vice President of Clinical Development |
Alethia Young | Cantor Fitzgerald |
Kelsey Goodwin | Guggenheim Securities |
Ben Burnett | Stifel |
Matt Biegler | Oppenheimer |
Amanda Murphy | BTIG |
Biren Amin | Jefferies |
Jim Birchenough | Wells Fargo |
Mara Goldstein | Mizuho |
Daina Graybosch | SVB Leerink |
Welcome to the Fate Therapeutics Third Quarter 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on Investors & Media section of Fate's Web site at fatetherapeutics.com.
As a reminder, today's call is being recorded.
I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics.